Gainplan’s Gilead Sciences GILD Stock Holding History

Gainplan’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,500	Closed	-$284K	–	16
2017 Q3	$284K	Buy	+3,500	New	+$268K	0.15%	10

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Gainplan's GILD Position: Q4 2017 in Review

Gainplan sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 3,500 shares — an estimated $284K sold.

Gainplan first reported a position in GILD in Q3 2017 and held it in 1 quarter. The position peaked at $284K in Q3 2017. 1,576 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

Gainplan reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
Gainplan sold 3,500 Gilead Sciences shares in Q4 2017, an estimated $284K.
Gainplan first reported a position in Gilead Sciences in Q3 2017 and held it in 1 quarter.
Gainplan's Gilead Sciences position peaked at $284K in Q3 2017.
1,576 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on Gainplan's 13F filing for Q4 2017, filed 8 Feb 2018.